A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Conditions: NHL; Cutaneous T Cell Lymphoma; Peripheral T-cell Lymphoma Interventions: Biological: BITR2101 Sponsors: Boston Immune Technologies and Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials
Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
Conditions: Cutaneous T-Cell Lymphoma Interventions: Diagnostic Test: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / S ézary syndrome (SS). Sponsors: Instituto de Investigaci ón Biomédica de Salamanca; Carlos III Health Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type; T-lymphoblastic Lymphoma Interventions: Drug: Linperlisib; Drug: Camrelizumab; Drug: Pegaspargase; Drug: Dexamethasone Sponsors: Beijing Tongren Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Circulating Tumor DNA in Peripheral T-cell Lymphomas
Conditions: Peripheral T-cell Lymphoma; NK/T-Cell Lymphoma Interventions: Diagnostic Test: Tumor-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay; Diagnostic Test: 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) Sponsors: University of Aarhus; Aarhus University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Chimeric antigen receptor treatment targeting cd70 (seventy)
Conditions: Leukemia, Myeloid, Acute; Leukemia, B-cell; Leukemia, T-Cell; Lymphoma Interventions: Biological: Treatment Arm A Sponsors: Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Interventions: Drug: Sintilimab+Pegaspargase; Drug: P-GemOx; Drug: GELAD; Radiation: IMRT Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or S ézary Syndrome Previously Treated With Systemic Therapy
Conditions: Cutaneous T-Cell Lymphoma Interventions: Drug: Mogamulizumab Sponsors: Kyowa Kirin China Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
Conditions: Extranodal Natural Killer T Cell Lymphoma Interventions: Drug: chidamide, anti-PD1 antibody, and pegaspargase; Drug: DDGP Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
GVM ±R in Patients With Relapsed or Refractory Aggressive NHL.
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B-cell Lymphoma Interventions: Drug: GVM ±R regimen Sponsors: Qiu Lugui Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Conditions: T-cell Lymphoma Interventions: Biological: hNeo-T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: BGI, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
Conditions: Angioimmunoblastic T-cell Lymphoma Interventions: Drug: mitoxantrone liposome 16 and azacitidine; Drug: mitoxantrone liposome 18 and azacitidine; Drug: mitoxantrone liposome 20 and azacitidine Sponsors: Huijing Wu; Beijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Chi-GVM Regimen for the Treatment of R/R PTCL
Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma Interventions: Drug: Chi-GVM Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Conditions: CD30-Positive Diffuse Large B-Cell Lymphoma; Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type; Anaplastic Large Cell Lymphoma, ALK-Positive; Peripheral T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative; Non-Hodgkin Lymphoma; Hodgkin Lymphoma Interventions: Biological: C7R.CD30.CAR-EBVST cells Sponsors: Baylor College of Medicine; The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma
Conditions: Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma Interventions: Drug: Azacytidine plus CAOLD regimen Sponsors: Navy General Hospital, Beijing; Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials
